Cytokinetics, Incorporated logo
Cytokinetics, Incorporated CYTK
$ 62.47 2.69%

Annual report 2025
added 02-26-2026

report update icon

Cytokinetics, Incorporated Financial Statements 2011-2026 | CYTK

Annual Financial Statements Cytokinetics, Incorporated

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

7.55 M 5.29 M 7.11 M 3.88 M 3.5 M 1.34 M 740 M 378 M 455 M 401 M 299 M 253 M 219 M 120 M 73.6 M

Shares

120 K 112 K 96.5 K 89.8 K 76.9 K 64.5 K 57.6 M 54.4 M 49.4 M 39.9 M 38.8 M 35.7 M 27.3 M 18.1 M 11.8 M

Historical Prices

62.8 47.3 73.6 43.2 45.6 20.8 10.6 6.32 8.15 12.2 10.5 8.01 6.5 3.96 5.76

Net Income

-785 M -590 M -526 M -389 M -215 M -127 M -122 M -106 M -128 M 16.5 M -37.5 M -14.6 M -33.7 M -40.4 M -47.9 M

Revenue

88 M 18.5 M 7.53 M 94.6 M 70.4 M 55.8 M 26.9 M 31.5 M 13.4 M 106 M 28.7 M 46.9 M 30.6 M 7.56 M 4 M

Gross Profit

- - - - - - - -57.6 M - - 28.7 M 46.9 M 30.6 M 7.56 M 4 M

Operating Income

-612 M -536 M -496 M -324 M -186 M -93.9 M -98.9 M -88.9 M -113 M 18.7 M -37.4 M -14.8 M -33.9 M -40.5 M -48 M

Interest Expense

45.6 M 37.7 M 28.3 M 19.4 M 16.4 M 16 M 6.62 M 3.8 M 3.02 M 2.7 M 268 K - - 3 K 35 K

EBITDA

-602 M -527 M -484 M -318 M -184 M -92.1 M -97.6 M -87.7 M -111 M 19.4 M -36.8 M -14.3 M -33.5 M -39.9 M -45.5 M

Operating Expenses

700 M 555 M 504 M 419 M 257 M 150 M 126 M 120 M 127 M 87.7 M 66.1 M 61.7 M 64.5 M 48.1 M 50.8 M

General and Administrative Expenses

284 M 215 M 174 M 178 M 96.8 M 52.8 M 39.6 M 31.3 M 36.5 M 27.8 M 19.7 M 17.3 M 15.1 M 12.4 M 13.6 M

All numbers in USD currency

Quarterly Income Statement Cytokinetics, Incorporated

2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

120 K 119 K 118 K 118 K 109 K 102 K 96.1 K 95.8 K 95.2 K - 93.8 K 85.7 K 85 K 84.8 M 80.3 K 71.8 K 71.2 K 71 M 68.3 K 59.6 K 59.3 K 59.2 M 58.6 K 57.6 K 54.8 K 54.7 M 54.6 M 54.3 M 54.1 M 54 M 53.7 M 48.2 M 41.6 M 40.6 M 39.9 M 39.7 M 39.6 M 39.6 M 38.8 M 38.7 M 38.7 M 38.7 M 36.6 M 36.4 M 33 M 30.7 M 29.4 M 25.8 M 24 M 23.7 M 22.4 M 13.5 M 76.1 M 74.9 M 72.3 M 71.2 M 74.9 M

Net Income

-306 M -134 M -161 M -161 M -143 M -136 M -129 M -129 M -131 M - -142 M -19.8 M -89.4 M - -76.1 M -61.6 M -47.1 M - -3.18 M -40.8 M -39.4 M - -29.6 M -32.1 M -29.4 M - -22 M -27.5 M -30.3 M -40.5 M -32.4 M -29.1 M -25.9 M 7.16 M 33.4 M -11.6 M -12.5 M -9.23 M -8.85 M -10.6 M -8.87 M 8.44 M -5.97 M -8.37 M -8.74 M 6.53 M -12.6 M -15 M -12.6 M -11.5 M -10 M -8.94 M -9.93 M -11.9 M -10.6 M -13.6 M -11.7 M

Revenue

1.94 M 66.8 M 1.58 M 463 K 249 K 835 K 378 K 867 K 4.61 M - 2.52 M 89 M 1.15 M - 5.44 M 2.84 M 6.55 M - 41.7 M 3.59 M 3.82 M - 6.06 M 7.14 M 8.46 M - 10.6 M 6.22 M 5.27 M -18 K 6.18 M 3.05 M 4.15 M 33.1 M 59 M 5.8 M 8.42 M 9.76 M 7.94 M 6.54 M 4.41 M 21.8 M 9.42 M 7.79 M 7.98 M 24.3 M 4.47 M 1.01 M 821 K 2.18 M 1.71 M 1.84 M 1.82 M 757 K 1.43 M 1.05 M 763 K

Operating Income

-167 M -112 M -156 M -141 M -130 M -126 M -122 M -122 M -124 M - -108 M -10.9 M -77.9 M - -69.2 M -54.8 M -40.6 M - 5.18 M -32.4 M -30.4 M - -23.9 M -26.7 M -24.5 M - -17.9 M -23.4 M -26.1 M - -28.4 M -25.2 M -23.3 M - 34 M -11 M -12 M - -8.89 M -10.6 M -8.91 M - -6 M -8.41 M -8.77 M - -12.6 M -15.1 M -12.6 M - -10.1 M -8.96 M -9.94 M - -10.7 M -13.6 M -11.8 M

Interest Expense

11.4 M 11.1 M - 8.93 M 12.7 M - 7.14 M 7.04 M 6.96 M - 6.8 M 2.81 M 2.75 M - 4.16 M 4.07 M 3.99 M - 3.98 M 3.89 M 4.08 M - 1.34 M 1.38 M 1.17 M - 867 K 898 K 863 K - 806 K 782 K 745 K - 714 K 707 K 563 K - - - - - - - - - - - - - - - - - - - -

EBITDA

- - -153 M - - -124 M - - -123 M - -104 M -10.9 M -76.5 M - -67.7 M -54.8 M -40.1 M - 6.54 M -31.5 M -30 M - -23 M -26.2 M -24.2 M - -16.4 M -22.1 M -25.5 M - -27.1 M -24.3 M -22.8 M - 34.5 M -10.7 M -11.8 M - -8.45 M -10.3 M -8.76 M - -5.64 M -8.18 M -8.66 M - -12.3 M -14.8 M -12.5 M - -9.61 M -8.63 M -9.76 M - -9.6 M -12.8 M -11.3 M

Operating Expenses

169 M 178 M 157 M 141 M 130 M 127 M 123 M 123 M 129 M - 111 M 99.8 M 79 M - 74.6 M 57.6 M 47.2 M - 36.5 M 36 M 34.2 M - 30 M 33.9 M 33 M - 28.6 M 29.6 M 31.4 M - 34.6 M 28.2 M 27.4 M - 25.1 M 16.8 M 20.4 M - 16.8 M 17.1 M 13.3 M - 15.4 M - - - - - - - - - - - - - -

General and Administrative Expenses

69.5 M 65.7 M 57.4 M 56.7 M 50.8 M 45.5 M 40.1 M 39.7 M 49.7 M - 48.2 M 42.7 M 33.1 M - 26.2 M 21.2 M 15.6 M - 12.3 M 14.2 M 12.4 M - 9.75 M 9.84 M 9.44 M - 7.16 M 8.05 M 9.26 M - 9.66 M 8.44 M 8.12 M - 7.22 M 7.09 M 6.84 M - 5.28 M 4.5 M 4.37 M - 3.99 M 4.46 M 4.26 M - 3.64 M 3.73 M 3.63 M - 2.99 M 2.57 M 3.06 M - 3.2 M 4.19 M 3.34 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Cytokinetics, Incorporated CYTK
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Cytokinetics, Incorporated plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.54 -0.7 % $ 1.06 B canadaCanada
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
AC Immune SA AC Immune SA
ACIU
$ 3.25 3.83 % $ 229 M schweizSchweiz
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 4.16 -1.42 % $ 105 M schweizSchweiz
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.8 1.81 % $ 4.36 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
argenx SE argenx SE
ARGX
$ 712.23 1.27 % $ 25 B niderlandNiderland
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 228.93 -0.91 % $ 5 B danmarkDanmark
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.39 -6.09 % $ 8.16 B australiaAustralia
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 6.15 1.57 % $ 501 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 6.62 -0.15 % $ 181 M israelIsrael
BioCardia BioCardia
BCDA
$ 1.35 6.29 % $ 28.6 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.58 -0.28 % $ 7.79 B israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 11.29 -2.51 % $ 1.01 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.58 1.53 % $ 214 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
$ 2.32 -5.51 % $ 887 K usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.69 1.7 % $ 16.9 M usaUSA
Curis Curis
CRIS
$ 0.89 3.74 % $ 5.61 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 93.04 2.76 % $ 27.2 B germanyGermany
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.51 -0.33 % $ 385 M britainBritain
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany